- |||||||||| NCS-01 / NC Medical Research
Trial completion date, Trial primary completion date: A Study of NCS-01 in Patients With Acute Ischemic Stroke (clinicaltrials.gov) - Oct 10, 2023
P1/2, N=16, Recruiting,
Recruiting --> Active, not recruiting Trial completion date: Oct 2024 --> Oct 2028 | Trial primary completion date: Oct 2023 --> Oct 2027
- |||||||||| NCS-01 / NC Medical Research
Trial completion date, Trial primary completion date: A Study of NCS-01 in Patients With Acute Ischemic Stroke (clinicaltrials.gov) - Apr 25, 2022
P1/2, N=16, Recruiting,
Available on Wednesday, February 08, 2023 at 08:00am CST. Trial completion date: Oct 2021 --> Oct 2024 | Trial primary completion date: Oct 2021 --> Oct 2023
- |||||||||| NCS-01 / NC Medical Research
Review, Journal: Bone marrow-derived NCS-01 cells for ischemic stroke. (Pubmed Central) - Jun 5, 2021
NCS-01 cells, in comparison with other lines of stem cells (Li cells), are shown to produce greater therapeutic effects, most likely due to the observed filopodia formation that allows the stem cells to extend and target the ischemic cells. Given these findings, NCS-01 stem cells serve as a potential treatment for stroke through the demonstration of profound efficacy and further research that favors their filopodia-mediated mechanism of action.
- |||||||||| NCS-01 / NC Medical Research
Review, Journal: Bone Marrow-Derived NCS-01 Cells Advance a Novel Cell-Based Therapy for Stroke. (Pubmed Central) - Jan 23, 2021
In this review, we discuss recent preclinical advancements using in vitro and in vivo ischemia models that support the transplantation of NCS-01 in human stroke trials. These results, coupled with the recommendations put forth by the consortium of Stem cell Therapeutics as an Emerging Paradigm for Stroke (STEPS), highlight a framework for conducting preclinical research with the ultimate goal of initiating clinical trials.
- |||||||||| NCS-01 / NC Medical Research
Enrollment open, Trial initiation date: A Study of NCS-01 in Patients With Acute Ischemic Stroke (clinicaltrials.gov) - Mar 2, 2020
P1/2, N=16, Recruiting,
These results, coupled with the recommendations put forth by the consortium of Stem cell Therapeutics as an Emerging Paradigm for Stroke (STEPS), highlight a framework for conducting preclinical research with the ultimate goal of initiating clinical trials. Not yet recruiting --> Recruiting | Initiation date: Aug 2019 --> Feb 2020
|
